Decoding the potential link between Covid-19 and mucormycosis: Literature review
Abstract
Background: Mucorales, the causative agent of mu-cormycosis, is a life-threatening fungal infection that primarily affects immunocompromised hosts. This condition is becoming more severe during the current COVID-19 pandemic. The objective is to decipher the link between mucormycosis, steroids, and the associated co-morbidities of COVID-associated mucormycosis (CAM). This study is focussed on assessing the various aspects of COVID related mucormycosis. Aim: To systematically review the reported cases of CAM, clinical presentation with steroid therapy and associated comorbidities.
Materials and Methods: MeSH terms like mucormycosis, diabetes, SARS-CoV-2 infection, sinus, orbit, and palate were searched in the PUBMED and Google Scholar databases, and 20 case reports and case series were identified.
Results: We found that India had the highest number of cases (60%), 55% of the infected patients were male, 65% had a history of diabetes and the associated risk factor was uncontrolled diabetes (90%). The common clinical presentation among the cases was noted to be necrosis and swelling, with 55% of the cases reported to be rhino orbital mucormycosis. In most of the cases cytological and histological examination had been performed with haematoxylin & eosin, KOH, lactophenol cotton blue, and special stains such as PAS and GMS had been used in few cases along with culture in Sabouraud dextrose agar. Regarding treatment, 85% of the cases were treated with amphotericin B and in 15% of cases a combination of amphotericin B and posaconazole was employed. The rate of mortality reported was estimated to be 25%.
Conclusion: COVID-19 infection poses a significant threat to diabetic patients, increasing their susceptibility to mucormycosis. Therefore, the careful use of steroids and routine monitoring are essential in preventing this invasive infection.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. © 2024.
